Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients


Disclosures: T.M., S.Z. and N.W.C.J.vdD. received research support from Janssen Research and Development. S.Z. and N.W.C.J. vdD. participated in advisory boards organized by Janssen Pharmaceuticals.

Contributions: K.A.F., P.W.C.B., J.F.vV., P.L.A.F., M.P.G.K., G.F.R., A.C.B. and T.M. executed experiments, analyzed and interpreted the results; I.S.N., S.Z. and N.W.C.J.vdD. provided patient materials; K.A.F. and N.W.C.J.vdD. designed the study, interpreted the results and wrote the first draft of the manuscript; all authors helped critically review the manuscript and checked the final version of it.